Given the patient's pharmacogenomic profile (ADRA2A heterozygous, HLA‑A*3101 absent, HLA‑B*1502 absent, HTR2A G/G, SLC6A4 short/long heterozygous, CES1A1 normal metabolizer, CYP1A2 A/A, CYP2B6 normal, CYP2C19 normal, CYP2C9 intermediate, CYP2D6 normal, CYP3A4 normal, UGT1A4 ultrarapid, UGT2B15 intermediate, MTHFR heterozygous C/T, COMT Val/Met), what are the recommended pharmacologic treatment choices and dosing adjustments for ADHD, depression/anxiety, and other relevant conditions?

Pharmacogenomic-Guided Treatment Recommendations

ADHD Treatment

For ADHD, initiate methylphenidate as first-line therapy at standard starting doses, as this patient's ADRA2A C/G heterozygous genotype predicts normal-to-favorable response, and their CYP2D6 extensive metabolizer status ensures appropriate drug clearance. 1

Stimulant Selection and Dosing

• Methylphenidate (first-line): Start with standard dosing protocols. The patient's ADRA2A C/G genotype (one copy of the G allele) is associated with improved ADHD symptom response to methylphenidate 2. Meta-analysis demonstrates G-allele carriers experience significantly greater improvements in ADHD symptom scores (odds ratio 3.08) and higher response rates compared to non-carriers 2.

• **CYP2D6 *1/*2 (extensive metabolizer)**: This patient will metabolize methylphenidate normally, requiring no dose adjustments from standard protocols 1.

• Lisdexamfetamine (second-line): If methylphenidate proves inadequate after proper titration (3-4 weeks), switch to lisdexamfetamine rather than non-stimulants, as guidelines prioritize this sequence 1.

Non-Stimulant Options (Third-Line)

• Atomoxetine: The patient's CYP2D6 extensive metabolizer status means standard dosing applies. However, expect 6-12 weeks for full therapeutic effect 1. Note: Some evidence suggests the patient's ADRA2A genotype may influence atomoxetine response, though data are less robust than for methylphenidate 3.

• Alpha-2 agonists (guanfacine/clonidine): Reserve for specific comorbidities (sleep disorders, tics, disruptive behaviors) or as augmentation 1.

---

Depression/Anxiety Treatment

**For depression or anxiety, avoid paroxetine entirely due to this patient's HTR2A G/G genotype, which confers increased risk of adverse reactions; instead, select escitalopram or sertraline at standard starting doses, as the patient's CYP2C19 1/1 (extensive metabolizer) status ensures normal drug clearance. 4, 5

Critical Pharmacodynamic Consideration

• HTR2A -1438G>A polymorphism (G/G genotype): This patient is homozygous for the G allele, which is associated with increased risk of adverse drug reactions specifically with paroxetine 4. Avoid paroxetine.

SSRI Selection Based on Metabolizer Status

**CYP2C19 1/1 (extensive/normal metabolizer) 5:

• Escitalopram: Standard dosing (10-20 mg/day). Optimal choice given normal CYP2C19 metabolism.
• Sertraline: Standard dosing (50-200 mg/day). Minimal CYP2C19 impact; safe alternative.
• Citalopram: Standard dosing (20-40 mg/day), though escitalopram preferred for better tolerability.

**CYP2D6 1/2 (extensive/normal metabolizer) 5:

• Fluoxetine: Standard dosing (20-80 mg/day) acceptable, though note long half-life.
• Venlafaxine: Standard dosing (75-225 mg/day) if SNRI preferred.

Medications Requiring Caution

**CYP2C9 1/2 (intermediate metabolizer) 5:

• This primarily affects NSAIDs and warfarin, not antidepressants significantly. No major antidepressant dose adjustments needed.

SLC6A4 Consideration (Limited Clinical Utility)

• SLC6A4 L/S (short/long heterozygous): The short allele is associated with moderately decreased SSRI response in some studies 5, 6. However, current CPIC guidelines do not recommend using SLC6A4 genotype for clinical prescribing decisions 5. If initial SSRI response is suboptimal after 4-6 weeks at therapeutic doses, consider:
  • Dose escalation to upper therapeutic range
  • Switch to alternative SSRI or SNRI
  • Augmentation strategies

---

Additional Pharmacogenomic Considerations

Metabolizer Status Summary for Other Drug Classes

CYP1A2 -163C>A (A/A - highly inducible):

• Non-smoker: Extensive metabolizer for drugs like duloxetine, mirtazapine
• Smoker: Ultrarapid metabolizer; may require higher doses of CYP1A2 substrates
• If prescribing duloxetine (SNRI), adjust for smoking status

**UGT1A4 *1/*3 (ultrarapid metabolizer)**:

• Increased metabolism of lamotrigine (if mood stabilizer needed for bipolar spectrum)
• May require higher lamotrigine doses than typical

MTHFR C677T (C/T heterozygous):

• Moderately reduced enzyme activity
• Consider L-methylfolate augmentation (15 mg/day) if antidepressant response inadequate 7
• Some evidence supports improved outcomes with folate supplementation in MTHFR variants

COMT Val/Met (heterozygous):

• Intermediate dopamine catabolism
• Theoretical implications for stimulant response, but insufficient evidence for clinical decision-making 7

---

Practical Algorithm

For ADHD:

1. Start methylphenidate (immediate or extended-release based on coverage needs)
2. Titrate over 3-4 weeks to optimal dose
3. If inadequate response → switch to lisdexamfetamine
4. If stimulants contraindicated/ineffective → atomoxetine (standard dosing, 6-12 week trial)

For Depression/Anxiety:

1. Avoid paroxetine (HTR2A G/G risk)
2. Start escitalopram 10 mg/day or sertraline 50 mg/day
3. Titrate to therapeutic range over 4-6 weeks
4. If partial response and SLC6A4 S/L present → escalate to upper dosing range
5. If inadequate response → switch to alternative SSRI or consider SNRI (venlafaxine, duloxetine)
6. Consider L-methylfolate 15 mg augmentation (MTHFR variant)

Key Monitoring Parameters:

• ADHD medications: Height, weight, pulse, blood pressure
• Antidepressants: Suicidality (especially first 4 weeks), clinical worsening, activation symptoms
• Smoking status: Reassess if prescribing CYP1A2 substrates (duloxetine)

---

Critical Pitfalls to Avoid

1. Do not prescribe paroxetine to this patient under any circumstances given HTR2A G/G genotype 4
2. Do not assume SLC6A4 or COMT genotypes mandate treatment changes—these lack sufficient evidence for clinical actionability 5, 7
3. Do not overlook smoking status when prescribing CYP1A2 substrates; this patient's A/A genotype makes them highly inducible
4. Do not abandon methylphenidate prematurely for ADHD—the ADRA2A G-allele predicts favorable response 2
5. Do not use CYP2C9 intermediate metabolizer status to adjust antidepressant dosing; this primarily affects other drug classes